115 related articles for article (PubMed ID: 28092999)
1. Second malignancies in survivors of chronic myelomonocytic leukemia: a U.S. population-based study.
El-Fattah MA
Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28092999
[No Abstract] [Full Text] [Related]
2. Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States.
Guru Murthy GS; Dhakal I; Mehta P
Leuk Lymphoma; 2017 Jul; 58(7):1648-1654. PubMed ID: 27881041
[TBL] [Abstract][Full Text] [Related]
3. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia.
Kumar V; Ailawadhi S; Bojanini L; Mehta A; Biswas S; Sher T; Roy V; Vishnu P; Marin-Acevedo J; Alegria VR; Paulus A; Aulakh S; Iqbal M; Manochakian R; Tan W; Chanan-Khan A; Ailawadhi M
Blood Cancer J; 2019 Sep; 9(10):75. PubMed ID: 31570695
[TBL] [Abstract][Full Text] [Related]
4. Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries.
Benzarti S; Daskalakis M; Feller A; Bacher VU; Schnegg-Kaufmann A; Rüfer A; Holbro A; Schmidt A; Benz R; Solenthaler M; Stussi G; Arndt V; Bonadies N;
Cancer Epidemiol; 2019 Apr; 59():51-57. PubMed ID: 30690330
[TBL] [Abstract][Full Text] [Related]
5. Second primary lung cancer in United States Cancer Survivors, 1992-2008.
Donin NM; Kwan L; Lenis AT; Drakaki A; Chamie K
Cancer Causes Control; 2019 May; 30(5):465-475. PubMed ID: 30900065
[TBL] [Abstract][Full Text] [Related]
6. Second malignancy in young early-stage breast cancer patients with modern radiotherapy: A long-term population-based study (A STROBE-compliant study).
Xie L; Lin C; Zhang H; Bao X
Medicine (Baltimore); 2018 Apr; 97(17):e0593. PubMed ID: 29703057
[TBL] [Abstract][Full Text] [Related]
7. Second primary malignancies in adult acute myeloid leukemia--A US population-based study.
Ghimire KB; Shah BK
Anticancer Res; 2014 Jul; 34(7):3855-9. PubMed ID: 24982414
[TBL] [Abstract][Full Text] [Related]
8. Solutions bring new problems: secondary cancers are a risk for some survivors.
Nelson NJ
J Natl Cancer Inst; 1997 Oct; 89(20):1483-5. PubMed ID: 9337343
[No Abstract] [Full Text] [Related]
9. Risks for noncutaneous second primary malignancy in cutaneous malignant melanoma survivors: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) program.
Vakharia PP; Kelm RC; Orrell KA; Patel KR; Singam V; Ali Y; Rastogi S; Yousif R; Rangel SM; West DP; Nardone B
Int J Dermatol; 2020 Apr; 59(4):463-468. PubMed ID: 31971260
[TBL] [Abstract][Full Text] [Related]
10. Second primary malignancies in adult acute lymphoblastic leukemia: a US population-based study.
Ghimire KB; Shah BK
Blood; 2014 Sep; 124(12):2000-1. PubMed ID: 25237181
[No Abstract] [Full Text] [Related]
11. Second cancers in survivors of plasmacytoma of bone in the U.S.A: a SEER database analysis.
El-Fattah MA
Leuk Lymphoma; 2017 Dec; 58(12):2952-2956. PubMed ID: 28402206
[No Abstract] [Full Text] [Related]
12. Association of Treatment for Hodgkin Lymphoma With Estrogen Receptor Status of Subsequent Breast Cancers.
Withrow DR; Morton LM; Curtis RE; Schonfeld SJ; Berrington de González A
JAMA Oncol; 2018 Mar; 4(3):414-416. PubMed ID: 29346498
[TBL] [Abstract][Full Text] [Related]
13. Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
Casper AC; Parsons MW; Chipman J; Burt LM; Suneja G; Maurer KA; Gaffney DK
Gynecol Oncol; 2021 Aug; 162(2):454-460. PubMed ID: 34092413
[TBL] [Abstract][Full Text] [Related]
14. Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database.
Guru Murthy GS; Szabo A; Michaelis L; Carlson KS; Runaas L; Abedin S; Atallah E
J Natl Compr Canc Netw; 2020 Feb; 18(2):169-175. PubMed ID: 32023530
[TBL] [Abstract][Full Text] [Related]
15. Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.
Khanal A; Budhathoki N; Singh VP; Shah BK
Anticancer Res; 2017 Apr; 37(4):2033-2036. PubMed ID: 28373478
[TBL] [Abstract][Full Text] [Related]
16. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.
Hisada M; Chen BE; Jaffe ES; Travis LB
J Natl Cancer Inst; 2007 Feb; 99(3):215-22. PubMed ID: 17284716
[TBL] [Abstract][Full Text] [Related]
17. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer.
Brown AP; Chen J; Hitchcock YJ; Szabo A; Shrieve DC; Tward JD
J Clin Endocrinol Metab; 2008 Feb; 93(2):504-15. PubMed ID: 18029468
[TBL] [Abstract][Full Text] [Related]
18. Racial and ethnic differences in risk of second primary cancers among breast cancer survivors.
Calip GS; Law EH; Ko NY
Breast Cancer Res Treat; 2015 Jun; 151(3):687-96. PubMed ID: 26012645
[TBL] [Abstract][Full Text] [Related]
19. Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma--a SEER based study.
Chakraborty S; Hauke RJ; Bonthu N; Tarantolo SR
Anticancer Res; 2012 Oct; 32(10):4507-15. PubMed ID: 23060579
[TBL] [Abstract][Full Text] [Related]
20. Risk of second malignancies among survivors of pediatric thyroid cancer.
Adly MH; Sobhy M; Rezk MA; Ishak M; Afifi MA; Shafie AE; Ali MA; Zekri W; Alfaar AS; Rashed WM
Int J Clin Oncol; 2018 Aug; 23(4):625-633. PubMed ID: 29492793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
